Mark J. Rivard
Tufts University
222 Papers
1.6K Citations
Mark J. Rivard is an academic researcher from Tufts University. The author has contributed to research in topics: Brachytherapy & Dosimetry. The author has an hindex of 41, co-authored 210 publications. Previous affiliations of Mark J. Rivard include Shiraz University & Rhode Island Hospital.
Chat about Author
Papers
Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.
Mark J. Rivard,Bert M. Coursey,Larry A. DeWerd,William F. Hanson,M. Saiful Huq,Geoffrey S. Ibbott,Michael G. Mitch,Ravinder Nath,Jeffrey F. Williamson +8 more
TL;DR: An update of the TG-43 protocol for calculation of dose-rate distributions around photon-emitting brachytherapy sources is presented, and a unified approach to comparing reference dose distributions derived from different investigators to develop a single critically evaluated consensus dataset is recommended.
1.6K
Update of the AAPM task group no. 43 report - a revised AAPM protocol for brachytherapy dose calculations
Mark J. Rivard,Bert M. Coursey,Larry A. DeWerd,William F. Hanson,M.S. Huq,Geoffrey S. Ibbott,Michael G. Mitch,Ravinder Nath,Jeffrey F. Williamson +8 more
TL;DR: An update of the TG-43 protocol for calculation of dose-rate distributions around photon-emitting brachytherapy sources is presented, and a unified approach to comparing reference dose distributions derived from different investigators to develop a single critically evaluated consensus dataset is recommended.
1.3K
Report of the Task Group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: current status and recommendations for clinical implementation.
Luc Beaulieu,Åsa Carlsson Tedgren,Jean-François Carrier,S Davis,Firas Mourtada,Mark J. Rivard,Rowan M. Thomson,Frank Verhaegen,Todd A. Wareing,Jeffrey F. Williamson +9 more
TL;DR: The charge of Task Group 186 (TG-186) is to provide guidance for early adopters of model-based dose calculation algorithms (MBDCAs) for brachytherapy (BT) dose calculations to ensure practice uniformity, with explicit recommendations based on the current state of knowledge.
505
The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma
E. Rand Simpson,Brenda L. Gallie,Normand Laperrierre,Akbar Beiki-Ardakani,Tero Kivelä,Virpi Raivio,Jorma Heikkonen,Laurence Desjardins,Rémi Dendale,A. Mazal,Norbert Bornfeld,Wolfgang Sauerwein,D. Fluehs,Lorenzo Brualla,Santosh G Honavar,Vijay Anand P. Reddy,Shigenobu Suzuki,Naoya Murakami,S.V. Saakyan,Vladimir Valskiy,Anush Amiryan,Stefan Seregard,Charlotta All-Eriksson,Lars Hjelmqvist,Göran Lundell,Georges Sinclair,Marie Lundell,Bertil Damato,R Doug Errington,P. Mayles,Helen Mayles,Chris S. Bergstrom,Hans E. Grossniklaus,Ian R. Crocker,Elizabeth Butker,Matthew W. Wilson,Barrett G. Haik,Holger Geischen,Pradeep Patra,Jay S. Duker,John E. Mignano,Mark J. Rivard,Paul T. Finger,Ekaterina Semenova,Walter Choi,Nina Kalach +45 more
TL;DR: The American Brachytherapy Society (ABS) as mentioned in this paper developed a set of guidelines for plaque brachythermytherapy of choroidal melanoma and retinoblastoma.
313
Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM
Christian Kirisits,Mark J. Rivard,Dimos Baltas,Facundo Ballester,Marisol De Brabandere,Rob van der Laarse,Yury Niatsetski,Panagiotis Papagiannis,Taran Paulsen Hellebust,Taran Paulsen Hellebust,Jose Perez-Calatayud,Kari Tanderup,Jack L.M. Venselaar,Frank-André Siebert +13 more
TL;DR: The recommended comprehensive uncertainty investigations are key to obtain a general impression of uncertainties, and may help to identify elements of the brachytherapy treatment process that need improvement in terms of diminishing their dosimetric uncertainties.
298